Sepracor taps Adams as CEO

Share this article:
Sepracor named Adrian Adams CEO, replacing Timothy Barberich, who was elected executive chairman of the company’s board of directors. Adams appointment had been anticipated since his hiring as COO on March 1. Adams, who will retain title of president, was previously CEO at Kos Pharmaceuticals from 2002 until the acquisition of the company by Abbott Laboratories in December 2006 for $3.7 billion. Adams is a 30-year veteran of the pharmaceutical industry with experience in national and international product marketing, R&D, sales, business development and general management with companies including ICI, SmithKline Beecham and Novartis.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union